Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.

被引：0

作者：

Janne, Pasi A.

Goto, Yasushi

Kubo, Toshio

Ninomiya, Kiichiro

Kim, Sang-We

Planchard, David

Ahn, Myung-Ju

Smit, Egbert F.

De langen, Adrianus Johannes

Perol, Maurice

Pons-Tostivint, Elvire

Novello, Silvia

Hayashi, Hidetoshi

Shimizu, Junichi

Kim, Dong-Wan

Pereira, Kaline

Cheng, Fu-Chih

Taguchi, Ayumi

Cheng, Yingkai

Goto, Koichi

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[3] Okayama Univ Hosp, Okayama, Japan

[4] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea

[5] Inst Gustave Roussy, Villejuif, France

[6] Sungkyunkwan Univ, Dept Hematol Oncol, Samsung Med Ctr, Sch Med, Seoul, South Korea

[7] Netherlands Canc Inst, Amsterdam, Netherlands

[8] Leon Berard Canc Ctr, Dept Med Oncol, Lyon, France

[9] Nantes Univ Hosp Ctr, Nantes, France

[10] Univ Turin, Azienda Osped Univ San Luigi Gonzaga, Osaka, Japan

[11] Kindai Univ Hosp, Osaka, Japan

[12] Aichi Canc Ctr Hosp, Dept Thorac Oncol, Nagoya, Aichi, Japan

[13] Seoul Natl Univ Hosp, Seoul, South Korea

[14] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[15] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8543

引用

页数：1